All News
RheumNow Week in Review – 11 November 2016
Dr Cush reviews highlights from this week on RheumNow.com
Read Article
The Long Awaited PRECISION Study
The PRECISION study will be presented on Tuesday, November 15, 2016 by Dr. Elaine Husni from the Cleveland Clinic. This report brings to a climax the controversy ignited by the February 2005 3 day FDA Arthritis Advisory Committee review of the safety of the blockbuster COX-2 inhibitors, celecoxib, rofecoxib, and valdecoxib.
Read Article
Pfizer Features Xeljanz Presentations at ACR 2016
At this years 2016 ACR/ARHP Annual Meeting Pfizer will presen 20 abstracts, mostly centering around its JAK inhibitor tofacitinib (Xeljanz). They will also present the results of their Phase 3 OPAL studies of tofacitinib in patients with psoriatic arthritis.
Read Article
Lilly Features it's Rheumatoid and Psoriasis Biologics at ACR 2016
Eli Lilly & Co. has multiple presentations planned for the upcoming Annual meeting of the ACR/ARHP in Washington starting on Sunday, November 13th.
Read Article
Janssen's Portfolio of New Biologics Roll Out for ACR 2016
Janssen has announced the listings for it's presentations at the upcoming annual ACR/ARHP 2016 meeting in Washington.
Read Article
Agressive Early Treatment Prevents Rapid Bone Loss in Rheumatoid Arthritis
The International Osteoporosis Foundation has established the Chronic Inflammation and Bone Structure (CIBS) Working Group to address bone loss in rheumatoid arthritis (RA) and the role of biologic therapies. They conclude that early and aggressive treatment with biologic disease-modifying anti-rheumatic drugs will help prevent progressive bone loss in patients with RA.
Read Article
Do Statins Reduce Cardiovascular Disease in Rheumatoid Arthritis?
RA increases CV risk considerably. But whose responsibility is it to manage CV risk in RA patients?
Read Article
Enbrel Approved for Pediatric Chronic Plaque Psoriasis
Etanercept (Enbrel) received FDA approval Friday for use in children with moderate to severe, chronic plaque psoriasis. Previously approved for adults with plaque psoriasis the new indication will be for chronic plaque psoriasis for those over age 4 years.
Read Article
Decreased CD4 T Cells with Rituximab Infusions
Rituximab (RTX) is a monoclonal antibody directed against the CD20 antigen on B cells and when administered causes a marked depletion of CD20+ B cells.
Read Article
IgA ACPA and Plasmablasts Point to Microbiome in Pre-Clinical Rheumatoid
Serum antibodies precede the development of clinical rheumatoid arthritis (RAby) by many years, and yet we still have much to learn about this preclinical phase.
Read Article
When Cheap Generics Morph Into Expensive Prescriptions
The Wall Street Journal has reported an alarming trend in generic drug pricing that affects many, especially the elderly and those with arthrtis.
Read Article
Kawasaki Disease Pathogenesis Hinges on Interleukin-1
Researchers from the Toronto Hospital for Sick Children have published in the Journal of Immunology that a polymorphism in the inositol-triphosphate 3-kinase C (ITPKC) (rs28493229) is associated with the pathogenesis of Kawasaki's disease (KD).
Read Article
Seropositivity Increases Mortality Rates in Rheumatoid Arthritis
It has been long known that rheumatoid arthritis is associated with an increased mortality rate, especially in seropositive patients and those with extraarticular manifestations.
Read Article
Nor-Switch Study Shows it's Safe to Switch to a Biosimilar
The results of the Nor-Switch study were presented at the United European Gastroenterology annual congress this week demonstrating no significant difference in effect, adverse effects or antibody formation in patients switched from Remicade to the biosimilar infliximab (CT-P13, Remsima).
Read Article
Long-Term Outcomes of Aromatase Inhibitor Arthralgias
Aromatase inhibitors (AI) are often given in the setting of estrogen receptor-positive (ER+) breast cancer therapy.
Read Article
CDC Says Prevalence of Severe Joint Pain is Rising
The October 7th edition of MMWR reports that severe joint pain (SJP) has significantly risen from 10.5 million in 2012 to 27.2% in 2014, based on recent NHIS surveys.
Read Article
Biosimilar Reports – October 2016
RheumNow will periodically review this subject with “Biosimilar Reports” providing updates, news, new publications, overview articles and research results impacting to biosimilar development and use.
Read Article
The Arthritis Spectrum after Lyme Infection - Something New
Symptoms attributed to chronic Lyme disease are the bane of a rheumatologist’s existence. We often see patients referred for a variety of nonspecific complaints that do not resolve after antibiotic therapy, including the so-called post-Lyme disease syndrome.
Read Article
BUILD Study - Baricitinib Shows Rapid Efficacy and X-ray Protection
Baricitinib is an oral, small molecule, once-daily DMARD, that specifically inhibits Janus kinase 1 and 2 and is being developed for use in rheumatoid arthritis. With much of the developmental clinical trials completed, the drug is slated for review and potential approval near the end of the year.
Read Article
Recognizing Arboviral Infections in Rheumatic Disease Patients.
What does sex have to do with it? Although the Zika virus infection is known to be sexually transmitted, the same cannot be claimed for Dengue or Chikungunya.
Read Article
